Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05686083 · ClinicalTrials.gov registry record · NA
Pharmacokinetics of Two Fatty Acid Ketone Esters
A NA study of Pharmacokinetics, sponsored by BHB Therapeutics, Ireland.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05686083: Completed NA study of Pharmacokinetics, sponsored by BHB Therapeutics, Ireland.
NCT05686083 is a NA study of Pharmacokinetics that has completed, run by BHB Therapeutics, Ireland. The registered enrollment target is 12 participants, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05686083, a NA study of Pharmacokinetics, has completed, sponsored by BHB Therapeutics, Ireland.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Randomized, cross over pharmacokinetic study of a novel ketone di-ester and C6 ketone di-ester in ready to drink beverage matrices.
Primary Outcome
AUC of circulating metabolites in blood
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT C6 ketone di-ester
- DIETARY_SUPPLEMENT Novel ketone di-ester
Study Locations (1)
Illinois
- Biofortis - Addison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-01-30 |
| Est. Completion | 2023-03-31 |
| Phase | NA |
What the finished NCT05686083 record still lists
NCT05686083 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 62-participant average among 37 other Pharmacokinetics trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Pharmacokinetics appearing as the primary indexed condition, and to 2 interventions - of which C6 ketone di-ester is the first listed.
NCT05686083 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05686083 about?
NCT05686083 is a clinical study titled "Pharmacokinetics of Two Fatty Acid Ketone Esters". Randomized, cross over pharmacokinetic study of a novel ketone di-ester and C6 ketone di-ester in ready to drink beverage matrices.
What is the current status of trial NCT05686083?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2023-01-30. Estimated completion is 2023-03-31.
What conditions does trial NCT05686083 study?
This clinical trial studies the following conditions: Pharmacokinetics.
What interventions are being tested in trial NCT05686083?
The interventions under investigation include: C6 ketone di-ester (DIETARY_SUPPLEMENT), Novel ketone di-ester (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05686083?
This trial is sponsored by BHB Therapeutics, Ireland, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05686083 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacokinetics
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05686083's enrollment target sits among peer trials
12 32nd of 37 higher than 5 of 37 other Pharmacokinetics trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pharmacokinetics trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacokinetic Profile of N-Acetyl Cysteine
COMPLETED · NA
-
Interaction Between Cannabidiol, Meal Ingestion, and Liver Function
COMPLETED · NA
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose
RECRUITING · Phase 1
-
Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI